HedgePath Pharmaceuticals, Inc. announced that Stefan J. Cross, Dr. R. Dana Ono and W. Mark Watson, CPA have been appointed to HPPI's board of directors. Cross, 41, is the President of the US subsidiary of Mayne Pharma. Cross has more than 20 years of experience in the pharmaceutical industry.

Prior to his current appointment, he served the Vice President, Business and Corporate Development of Mayne Pharma's primary operating company, where he was responsible for all in-licensing and out-licensing programs and research and development partnerships. Through HPPI's recently finalized Supply and License Agreement transactions with Mayne Pharma Venture Pty Ltd, Mayne Pharma has the right to appoint a member of HPPI's board of directors. Ono, 61, is a co-founder and since 2000 has served as a Venture Partner of the VIMAC Milestone Medica Fund LP, a Boston-based early-stage life sciences fund co-sponsored by VIMAC Ventures LLC and RBC Technology Ventures, Inc. Dr. Ono has 30 years of experience in managing public and private life science companies, including, from 1995 to 2000, serving as President and Chief Executive Officer of IntraImmune Therapies, Inc., which was sold to Abgenix, Inc. in 2000.

Watson, 63, is a Certified Public Accountant with over 40 years experience in public accounting and auditing, having spent his entire career at Deloitte Touche Tohmatsu and its predecessor, most recently as Central Florida Marketplace Leader. He is expected to serve as Chairman of the Audit Committee of HPPI's board of directors.